March Medical Cannabis Headlines & Sector Update
March 2, 2026 | IN NEWS | BY Kate Thorpe
Each month, we bring together the key news stories shaping the medical cannabis landscape in the UK and beyond. From policy developments and emerging research to clinical practice, patient experience and sector growth, this update highlights the issues driving debate, influencing care, and affecting access for patients and clinicians alike.
It is designed to keep our members and stakeholders informed, grounded in evidence, and connected to what matters most across this rapidly evolving field.
Medical cannabis patient wins legal fight over wrongful driving conviction
A UK medical cannabis patient has won a Crown Court appeal after being wrongly convicted of driving with THC above the legal limit. At Winchester Crown Court on 10 February 2026, Sal Aziz, a legally prescribed medical cannabis patient, was fully acquitted of the charges after the prosecution failed to prove beyond reasonable doubt that the statutory medical defence did not apply.
While the case does not set a binding precedent, it clarifies the legal position on the use of controlled prescription medication beyond the expiry date. It also highlights the need for clear and consistent guidance on driving when prescribed medical cannabis.
Bristol Medical School to offer teaching placement in cannabis-based medicine
Bristol Medical School has formally approved what is believed to be one of the first student-selected medical cannabis teaching placements offered by a UK university. The programme has been developed by Dr David Tang, a Consultant in Emergency Medicine and member of the MCCS Expert Committee. It will introduce students to medical cannabis as a regulated therapeutic intervention within UK clinical practice.
While the study wasnāt designed to evaluate medical cannabis, the thresholds are not intended for use as a THC limit for those being prescribed cannabis, co-author Dr Rachel Lees Thorne said prescribing clinicians will need to ābalance the harms and risks of the treatment they provideā.
Is āreverse spin biasā an issue in medical cannabis research?
A recent peer-reviewed paper identified a previously unrecognised form of reporting bias that may be skewing how medical cannabis evidence is presented. The paper, published in Research Integrity and Peer Review, introduces the concept of reverse spin bias ā a pattern in which authors of systematic reviews ādiscount, downplay, or dismiss beneficial findings about a treatment despite their own evidence showing statistically significant effects. This phenomenon was observed repeatedly in studies on e-cigarettes for smoking cessation and medical cannabis for pain.
Franceās medical cannabis reimbursement plans revealed
The French medical cannabis framework is now in the final stage of decision-making before being implemented nationally. The Haute AutoritĆ© de SantĆ© (HAS), the body responsible for evaluating medicines and approving them for coverage under Franceās public health system, presented a draft for the pricing and reimbursement strategy this month. The proposed model establishes a tiered reimbursement structure tied directly to an assessment of each productās therapeutic benefit.
Join the Society
If you want to stay informed, supported, and part of the independent clinical voice shaping medical cannabis in the UK, join the Medical Cannabis Clinicians Society.
Membership gives you access to expert guidance, CPD-accredited education, peer support, and regular sector updates like this one. Join the Society to be part of the conversation and help drive better, evidence-based care.